DeepSyte™
Bill FeedAll repsScoreboardsPrimariesProAboutSign inGet started
DeepSyte™™

A nonpartisan civic accountability tool. We match federal legislation to your stated values — without partisan bias.

Learn

  • About
  • About the name
  • Methodology
  • Glossary

Legal

  • Privacy
  • Terms of Service
  • Refund Policy
  • Contact

Sources

Bill data from Congress.gov. Summaries from the Congressional Research Service where available.

Follow

  • Bluesky — @deepsyte.app
  • X — @deepsyteapp
All content is for informational purposes only. Always verify against primary sources.
Back to bill feed
118-s-326Introduced
Sign in to get alerts

VA Medicinal Cannabis Research Act of 2023

Read the record. Not the rhetoric.

See how your representatives voted on this bill.

DeepSyte matches this bill to the issues you care about and shows whether your reps' votes line up — not party, not press releases. Take the 2-minute values quiz to see your alignment.

Get started freeTake the values quiz

Alignment with your views

Sign in and take the values quiz to see how this bill lines up with what you've said.

Summary

Official CRS summary
This bill requires the Department of Veterans Affairs (VA) to study the effects of cannabis on veterans who are enrolled in the VA health care system and have been diagnosed with post-traumatic stress disorder (PTSD) or chronic pain (i.e., eligible veterans). First, the bill requires the VA to conduct an observational, 18-month study on the effects of cannabis on the health outcomes of eligible veterans. The VA must report on the study and address whether it is able to meet criteria necessary to conduct clinical trials. Then, if the VA determines that it is able to proceed, it must carry out a series of clinical trials on the effects of cannabis appropriate for investigational use, as determined by the Food and Drug Administration, on the outcomes of eligible veterans. The VA must carry out a long-term observational study of the clinical trial participants. The VA may terminate the trials if it is unable to meet clinical guideline requirements or the trials would create excessive risk to participants. The VA must ensure that the study and trials are representative of the demographics of veterans in the United States, as determined by the most recent data from the American Community Survey of the Bureau of the Census. The study and trials must include mechanisms to ensure data preservation and registration as necessary (in an anonymous form).
Read full bill text

Values analysis

Sign in and take the values quiz to get a personalized read on how this bill lines up with your positions.

Bill details

Congress
118
Bill type
s
Introduced
February 9, 2023
Sponsor
Not yet available
Last action
April 26, 2023— Motion by Senator Schumer to reconsider the vote by which cloture on the motion to proceed to S. 326 was not invoked (Record Vote No. 97) entered in Senate.

The recorded vote

U.S. SenateApr 26, 2023
45Yea37Nay

Counted from roll-call records for sitting members · source: congress.gov

How your representatives voted

Sign in to see how your representatives voted on this bill.